Table 2.
Changes from baseline metabolic parameters.
| Parameters | Sulodexide (N = 20) | Placebo (N = 20) | P value |
|---|---|---|---|
| Baseline BW (kg) | 72.9 ± 13.59 | 66.16 ± 13.11 | 0.119 |
| Change at end point (mmHg) | 0.24 ± 1.04 | −0.36 ± 1.44 | 0.144 |
| Baseline SBP (mmHg) | 128.8 ± 6.89 | 129 ± 12.01 | 0.949 |
| Change at end point (mmHg) | −1.25 ± 10.47 | −2.6 ± 15.01 | 0.743 |
| Baseline DBP (mmHg) | 73.85 ± 8.37 | 76.65 ± 8.16 | 0.291 |
| Change at end point (mmHg) | −1.6 ± 9.48 | −2.15 ± 8.94 | 0.851 |
| Baseline FPG (mg/dL) | 133.4 ± 31.29 | 142.38 ± 33.85 | 0.389 |
| Change at end point (mg/dL) | 1.65 ± 60.85 | 1.73 ± 42.35 | 0.818 |
| Baseline HA1C (%) | 7.41 ± 1.63 | 6.89 ± 0.94 | 0.232 |
| Change at end point (%) | −0.1 ± 1.49 | −0.05 ± 0.66 | 0.897 |
| Baseline LDL (mg/dL) | 86.8 ± 31.39 | 91.75 ± 31.77 | 0.623 |
| Change at end point (mg/dL) | −4.05 ± 34.51 | −2.6 ± 26.24 | 0.882 |
Data are mean SD; week 14 values compared with baseline.